https://www.selleckchem.com/products/unc0642.html
Triple negative breast cancer (TNBC) is an area of high unmet medical need in terms of new effective treatment strategies. Although breast cancer is traditionally considered a 'cold' tumor type, TNBC is the most appropriate subtype for immunotherapeutic strategies; this is due to the high level of tumor infiltrating lymphocytes, PD-L1 expression, and tumor mutational burden compared to other breast cancer subtypes. This review examines the available evidence on the use of immunotherapeutic strategies in early and advanced TNBC, discusse
Like
Comment
Share
